tetano
Editor, Senior Moderator
Hematology
. 2023 Dec;28(1):2288477.
doi: 10.1080/16078454.2023.2288477. Epub 2023 Dec 1. Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era
Xian Li[SUP] 1 [/SUP], Aiqi Zhao[SUP] 1 [/SUP], Huifang Jiang[SUP] 2 [/SUP], Ying Lu[SUP] 3 [/SUP], Jing Le[SUP] 4 [/SUP], Yaping Xie[SUP] 5 [/SUP], Meiwei Hu[SUP] 6 [/SUP], Hui Zeng[SUP] 7 [/SUP], Jianzhi Zhao[SUP] 8 [/SUP], Mei Zhou[SUP] 9 [/SUP], Hui Zhou[SUP] 10 [/SUP], Lili Chen[SUP] 11 [/SUP], Weiguo Zhu[SUP] 12 [/SUP], Guifang Ouyang[SUP] 13 [/SUP], Huiqing Qiu[SUP] 14 [/SUP], Songfu Jiang[SUP] 15 [/SUP], Qunyi Guo[SUP] 16 [/SUP], Wenbin Qian[SUP] 1 [/SUP], Yun Liang[SUP] 1 [/SUP]
Affiliations
Patients with hematologic malignancies are often immunodeficient and therefore have a higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We retrospectively examined a cohort of 289 patients from 16 hospitals in Zhejiang Province who had hematologic malignancies and COVID-19 during a period when the Omicron variant was predominant. Univariate analysis showed that some clinical characteristics, including elder age (P = 0.014), multiple comorbid conditions (P = 0.011), and receipt of active antineoplastic therapy (P = 0.018) were associated with an increased risk of severe COVID-19. Patients with severe/critical COVID-19 had significantly lower levels of lymphocytes and serum albumin, and significantly higher levels of D-dimer, lactate dehydrogenase, C-reactive protein, and interleukin-6 (all P < 0.05). Fifty-four patients (18.7%) had symptoms lasting ≥3 weeks, suggesting that persistent long-term COVID-19 infection is likely present in a significant proportion of patients. Receipt of the inactivated vaccine was unrelated to disease severity (P = 0.143), which indicated that many patients with hematologic malignancies may not have effective humoral immunity to inactivated vaccines.
Keywords: COVID-19; Chinese; clinical characteristics; hematologic malignancy; outcome; severe infection.
. 2023 Dec;28(1):2288477.
doi: 10.1080/16078454.2023.2288477. Epub 2023 Dec 1. Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era
Xian Li[SUP] 1 [/SUP], Aiqi Zhao[SUP] 1 [/SUP], Huifang Jiang[SUP] 2 [/SUP], Ying Lu[SUP] 3 [/SUP], Jing Le[SUP] 4 [/SUP], Yaping Xie[SUP] 5 [/SUP], Meiwei Hu[SUP] 6 [/SUP], Hui Zeng[SUP] 7 [/SUP], Jianzhi Zhao[SUP] 8 [/SUP], Mei Zhou[SUP] 9 [/SUP], Hui Zhou[SUP] 10 [/SUP], Lili Chen[SUP] 11 [/SUP], Weiguo Zhu[SUP] 12 [/SUP], Guifang Ouyang[SUP] 13 [/SUP], Huiqing Qiu[SUP] 14 [/SUP], Songfu Jiang[SUP] 15 [/SUP], Qunyi Guo[SUP] 16 [/SUP], Wenbin Qian[SUP] 1 [/SUP], Yun Liang[SUP] 1 [/SUP]
Affiliations
- PMID: 38038062
- DOI: 10.1080/16078454.2023.2288477
Patients with hematologic malignancies are often immunodeficient and therefore have a higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We retrospectively examined a cohort of 289 patients from 16 hospitals in Zhejiang Province who had hematologic malignancies and COVID-19 during a period when the Omicron variant was predominant. Univariate analysis showed that some clinical characteristics, including elder age (P = 0.014), multiple comorbid conditions (P = 0.011), and receipt of active antineoplastic therapy (P = 0.018) were associated with an increased risk of severe COVID-19. Patients with severe/critical COVID-19 had significantly lower levels of lymphocytes and serum albumin, and significantly higher levels of D-dimer, lactate dehydrogenase, C-reactive protein, and interleukin-6 (all P < 0.05). Fifty-four patients (18.7%) had symptoms lasting ≥3 weeks, suggesting that persistent long-term COVID-19 infection is likely present in a significant proportion of patients. Receipt of the inactivated vaccine was unrelated to disease severity (P = 0.143), which indicated that many patients with hematologic malignancies may not have effective humoral immunity to inactivated vaccines.
Keywords: COVID-19; Chinese; clinical characteristics; hematologic malignancy; outcome; severe infection.